Life Sciences

Featured thought leadership

• 

  2021 Healthcare and Life Sciences Investment Outlook

  Provides insights on how the political and regulatory environment, and market factors may impact investment decisions.

• 

  Revised Safe Harbor Protections for Prescription Drug Rebates

  HHS final rule requires pharmacy benefit managers to pass along prescription drug rebates to patients at the point of sale

• 

  Most Favored Nation Drug Pricing Model final rule

  On November 20, 2020, the Centers for Medicare and Medicaid Services announced the Most Favored Nation Drug Pricing Model

• 

  Generics 2030: Three strategies to curb the downward spiral

  By 2030, generics manufacturers will need to shift from the status quo and explore one of three avenues for change.

• 

  Health Plan Transparency in Coverage Final Rule

  HHS, Department of Labor, and Treasury finalized price transparency requirements for health plans set to take effect beginning in 2022

• 

  FDA final rule and guidance on importation of prescription drugs

  FDA finalized a rule and guidance allowing states to submit prescription drug importation proposals and manufacturers to re-label drugs for importation

• 

  Executive order on ‘Most-Favored-Nation’ drug pricing

  An Executive Order directs HHS rulemaking for “most favored nations” pricing for Medicare Part B and D drugs

• 

  COVID-19: Telemedicine and tax

  As telemedicine accelerates, the need for greater tax clarity and updated guidance relating to virtual healthcare is evident.

• 

  Executive orders on prescription drug costs

  Four Executive Orders (EO) described as action to deliver lower prescription drug prices to American Patients.

• 

  The clinical trial conundrum

  Failing to resume clinical trials could present as many risks to certain patients as COVID-19

• 

  Re-launching elective procedures

  An opportunity for medical device companies to shape their future customer base

• 

  KPMG Digital Lighthouse: Powering Life Sciences with advanced analytics

  The Life Sciences Industry is moving towards a dramatically different future based on a number of market drivers.

• 

  Diagnostics: Ramp-up of testing for COVID-19 & beyond

  Private labs seeking to restructure or build to deploy COVID-19 testing operations can benefit from KPMG’s rapid start-up approach

• 

  Restarting America – Practical Guide for Employers

  For businesses making decisions about when and how to reopen their businesses, here is a practical guide to key considerations.

• 

  Paycheck Protection Program and Health Care Enhancement Act

  Implications for Healthcare providers

• 

  Part D senior savings model for insulin coverage

  CMS just announced alternative Part D options that lower seniors’ cost-sharing for insulin, according to the attached issue brief.

• 

  Accelerated/advance payment for medicare providers and suppliers

  To learn more about enhancements to CMS’s Accelerated & Advance Payment Program to help providers & suppliers during COVID.

• 

  Coronavirus Aid, Relief, and Economic Security (CARES) Act

  Economic support and stimulus bill

• 

  2020 healthcare and life sciences investment outlook

  Analysis of the 2020 KPMG Healthcare and Life Sciences Investment Outlook survey sheds light on how the investment landscape will be impacted by influential disruptors, evolving market trends, and policy/regulatory developments.

• 

  The Race to EU MDR Compliance Continues

  Despite progress, companies are still facing many questions

• 

  Quality 2030

  Forward-thinking Life Sciences CXOs will transform Quality from a cost center to a value creator

• 

  Medical device regulatory affairs operational transformation

  Key insights and opportunities to unlock additional value by streamlining Regulatory Affairs operational activities

• 

  An open target

  Despite progress in corporate cybersecurity, life sciences operational technology is still vulnerable to increasingly sophisticated threats.

• 

  Global lessons in building a continuous improvement culture in healthcare

  Building a culture of excellence in healthcare

• 

  Embracing transparency

  Instead of viewing calls for transparency as a burden, pharmaceutical companies can take steps to turn pricing reform to their advantage.

• 

  Prescription drug rebates

  Proposed safe harbor changes open for comment

• 

  Part D Payment Modernization Model

  Consider applying for the voluntary initiative

• 

  Driving value from genomics in Life Sciences

  Rising to the data challenge

• 

  Opportunities in an evolving market

  2019 Health Care & Life Sciences Investment Outlook

• 

  R&D 2030

  Reinvent innovation and become an R&D front-runner by 2030

• 

  Digital transformation in regulatory affairs

  Unlocking value for life sciences organizations

• 

  Pharmaceuticals industry exec summary - Harvey Nash/KPMG CIO survey 2018

  This CIO Survey is the largest IT leadership study in the world, and summarizes what we learned about the transformational CIO.

• 

  The race to EU MDR compliance

  KPMG/RAPS survey illustrates the ground medical device companies still have to cover

• 

  Insider threat in life sciences

  2018 Program benchmark report

• 

  Digital health and disruption in diabetes

  Identifying opportunities for life sciences manufacturers.

• 

  Future of finance: Finance disrupted

  Innovation in the life sciences finance function

• 

  The disruption challenge

  As new entrants and cross-sector models abound, which direction should healthcare organizations turn?

• 

  Demystifying blockchain for life sciences

  Blockchain could be a key to interoperability and privacy

• 

  Revenue for the life sciences industry

  New standard. New challenges.

• 

  2018 Health care & life sciences investment outlook

  Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.